VANCOUVER, British Columbia, Feb. 07, 2024 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NF0), a leading biotechnology company dedicated to transforming mental health and addiction treatment, proudly announces…

VANCOUVER, British Columbia, Feb. 02, 2024 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE: 0NF0), a forefront biotechnology company dedicated to revolutionizing mental health and addiction treatment, announces…

MYCO announces it has received the issuance of a Notice of Allowance by the United States Patent and Trademark Office for MYCO-005 compound

DENVER, Nov. 28, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental…

VANCOUVER, British Columbia, Oct. 31, 2023 (GLOBE NEWSWIRE) — Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (CSE:MYCO) (AQSE:MYIG) (OTC:MYCOF) (FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to…